Mersana Therapeutics's market cap is currently ―. The company's EPS TTM is $-1.499; its P/E ratio is -2.99; Mersana Therapeutics is scheduled to report earnings on May 6, 2024, and the estimated EPS forecast is $-0.18. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22
Income Statement	-
Total Revenue	$ 10.70M	$ 7.70M	$ 10.65M	$ 7.80M	$ 14.69M
Gross Profit	$ 10.70M	$ 7.70M	$ 10.65M	$ 7.80M	$ 14.69M
EBIT	$ -18.50M	$ -40.64M	$ -53.28M	$ -55.18M	$ -45.83M
EBITDA	$ -18.38M	$ -41.26M	$ -54.74M	$ -56.27M	$ -46.61M
Net Income Common Stockholders	$ -19.54M	$ -41.66M	$ -54.31M	$ -112.33M	$ -89.85M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 174.56M	$ 186.28M	$ 128.73M	$ 122.83M	$ 128.88M
Total Assets	$ 226.06M	$ 262.90M	$ 311.00M	$ 296.19M	$ 334.34M
Total Debt	$ 33.63M	$ 34.34M	$ 35.03M	$ 35.68M	$ 36.30M
Net Debt	$ -140.93M	$ -151.94M	$ -93.70M	$ -87.14M	$ -92.58M
Total Liabilities	$ 189.16M	$ 210.71M	$ 221.20M	$ 231.90M	$ 242.28M
Stockholders Equity	$ 36.90M	$ 52.20M	$ 89.76M	$ 64.25M	$ 92.06M
Cash Flow	-
Free Cash Flow	$ -32.35M	$ -46.55M	$ -62.23M	$ -29.92M	$ -52.01M
Operating Cash Flow	$ -31.96M	$ -46.08M	$ -61.83M	$ -29.00M	$ -51.23M
Investing Cash Flow	$ 20.15M	$ 103.78M	$ -5.44M	$ 1.40M	$ -45.43M
Financing Cash Flow	$ 92.00K	$ -146.00K	$ 73.15M	$ 21.55M	$ 41.46M

Currency in USD

Mersana Therapeutics Earnings and Revenue History

Income Statement >

Mersana Therapeutics Debt to Assets

Balance Sheet >

Mersana Therapeutics Cash Flow

Cash Flow >

Mersana Therapeutics Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing